Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer

被引:200
作者
Fitzsimmons, D
Johnson, CD
George, S
Payne, S
Sandberg, AA
Bassi, C
Beger, HG
Birk, D
Büchler, MW
Dervenis, C
Cruz, LF
Friess, H
Grahm, AL
Jeekel, J
Laugier, R
Meyer, D
Singer, MW
Tihanyi, T
机构
[1] Univ Southampton, Univ Surg Unit, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England
[2] Univ Lund Hosp, S-22185 Lund, Sweden
[3] Olga Roma Hosp, Verona, Italy
[4] Univ Hosp Surg, Ulm, Germany
[5] Univ Bern, Inselspital, CH-3010 Bern, Switzerland
[6] AGIA OLGA Hosp, Athens, Greece
[7] Hosp Clin, Barcelona, Spain
[8] Univ Rotterdam Hosp, Rotterdam, Netherlands
[9] Hop Conception, Marseille, France
[10] Univ Heidelberg Hosp, D-68135 Mannheim, Germany
[11] Semmelweis Univ Med, H-1085 Budapest, Hungary
关键词
pancreatic neoplasm; quality of life; EORTC QLQ-C30; questionnaire;
D O I
10.1016/S0959-8049(99)00047-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is overwhelming consensus that quality of Life assessment is urgently required in pancreatic cancer, yet little research has been conducted. We report on the development of a disease specific questionnaire module to supplement the EORTC core cancer module, the QLQ-C30 in patients with pancreatic cancer, using EORTC quality of life study group guidelines for module development. Relevant QoL issues were generated from literature searches and interviews with health professionals and patients with pancreatic cancer. Issues were constructed into items and provisionally translated. The provisional module was pretested in patients in 8 European centres. The resulting module the QLQ-PAN26 includes 26 items related to disease symptoms, treatment side-effects and emotional issues specific to pancreatic cancer. This should ensure that the module will be sensitive to assess the small but important disease and treatment related QoL changes in pancreatic cancer. The use of the QLQ-C30 and QLQ-PAN26 will provide a comprehensive system of QoL assessment in international trials of pancreatic cancer. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:939 / 941
页数:3
相关论文
共 12 条
  • [1] AARONSON NK, 1993, JNCI-J NATL CANCER I, V2, P319
  • [2] Ahlgren JD, 1996, CANCER-AM CANCER SOC, V78, P654
  • [3] ALEXANDRE JH, 1992, THEOR SURG, V7, P18
  • [4] CANCER OF THE PANCREAS
    CARTER, DC
    [J]. GUT, 1990, 31 (05) : 494 - 496
  • [5] CULL A, 1994, EORTC QUALITY LFIE S
  • [6] Quality of life after treatment of pancreatic cancer
    Fitzsimmons, D
    Johnson, CD
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 1998, 383 (02) : 145 - 151
  • [7] FITZSIMMONS D, 1999, IN PRESS PSYCHO ONCO
  • [8] NO STANDARD TREATMENT IS AVAILABLE FOR ADVANCED PANCREATIC-CANCER
    LIONETTO, R
    PUGLIESE, V
    BRUZZI, P
    ROSSO, R
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (06) : 882 - 887
  • [9] Rothenberg ML, 1996, CANCER, V78, P627
  • [10] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER APPROACH TO QUALITY-OF-LIFE ASSESSMENT - GUIDELINES FOR DEVELOPING QUESTIONNAIRE MODULES
    SPRANGERS, MAG
    CULL, A
    BJORDAL, K
    GROENVOLD, M
    AARONSON, NK
    [J]. QUALITY OF LIFE RESEARCH, 1993, 2 (04) : 287 - 295